MA45680A - Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 - Google Patents
Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123Info
- Publication number
- MA45680A MA45680A MA045680A MA45680A MA45680A MA 45680 A MA45680 A MA 45680A MA 045680 A MA045680 A MA 045680A MA 45680 A MA45680 A MA 45680A MA 45680 A MA45680 A MA 45680A
- Authority
- MA
- Morocco
- Prior art keywords
- bispecific antibody
- proteins specifically
- binding
- type
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305923 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45680A true MA45680A (fr) | 2019-05-22 |
Family
ID=56507555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045680A MA45680A (fr) | 2016-07-18 | 2017-07-17 | Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241657A1 (fr) |
| EP (1) | EP3484924A1 (fr) |
| JP (2) | JP7071329B2 (fr) |
| KR (1) | KR20190028771A (fr) |
| CN (1) | CN109715665A (fr) |
| AR (1) | AR109264A1 (fr) |
| AU (1) | AU2017299125A1 (fr) |
| BR (1) | BR112019000770A2 (fr) |
| CA (1) | CA3030943A1 (fr) |
| CL (1) | CL2019000119A1 (fr) |
| CO (1) | CO2019001367A2 (fr) |
| CR (1) | CR20190072A (fr) |
| DO (1) | DOP2019000011A (fr) |
| EA (1) | EA201990321A1 (fr) |
| EC (1) | ECSP19011185A (fr) |
| IL (1) | IL264248A (fr) |
| MA (1) | MA45680A (fr) |
| MX (1) | MX2019000844A (fr) |
| PE (1) | PE20190514A1 (fr) |
| PH (1) | PH12019500122A1 (fr) |
| SG (1) | SG11201900400QA (fr) |
| TN (1) | TN2019000015A1 (fr) |
| TW (1) | TWI790206B (fr) |
| WO (1) | WO2018015340A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016116626A1 (fr) | 2015-01-23 | 2016-07-28 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| AU2019371243A1 (en) * | 2018-10-30 | 2021-05-27 | Bruker Spatial Biology, Inc. | Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies |
| WO2020183245A2 (fr) * | 2019-03-11 | 2020-09-17 | Janssen Pharmaceutica Nv | ANTICORPS BISPÉCIFIQUES ANTI-Vβ17/ANTI-CD123 |
| CN111171155B (zh) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
| TW202200618A (zh) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| UY39415A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadenas beta |
| EP4284512A1 (fr) | 2021-01-28 | 2023-12-06 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes de traitement du syndrome de libération de cytokines |
| CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
| EP4380693A1 (fr) * | 2021-08-06 | 2024-06-12 | Universität Basel | Variants de protéine de surface cellulaire discernables destinés à être utilisés en thérapie cellulaire |
| WO2023201226A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
| WO2024173830A2 (fr) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Cellules nk induites sensibles à des anticorps bispécifiques cd3/taa |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| WO1991006319A1 (fr) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Procedes et compositions de promotion de l'immunopotentialisation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AU9166691A (en) | 1990-12-20 | 1992-07-22 | Ixsys, Inc. | Optimization of binding proteins |
| CA2156725A1 (fr) | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR100259828B1 (ko) | 1995-09-11 | 2000-06-15 | 히라타 다다시 | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| CA2402081C (fr) | 2000-03-06 | 2015-09-22 | University Of Kentucky Research Foundation | Compose qui se lie selectivement au cd123 et qui utilise ce mecanisme pour tuer les progeniteurs dans les cancers hematologiques |
| MX346172B (es) | 2007-08-29 | 2017-03-10 | Sanofi - Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| EP2050764A1 (fr) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
| EP2370467B1 (fr) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Anticorps monocaténaire bispécifique pscaxcd3 (cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 ou fapalpha xcd3), spécifique d'espèces croisées |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| NO2748201T3 (fr) | 2011-08-23 | 2018-05-12 | ||
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| EP2839842A1 (fr) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations |
| CN105793285A (zh) * | 2013-12-10 | 2016-07-20 | 豪夫迈·罗氏有限公司 | 多亚基结构的亚基的结合结构域用于将药物活性实体靶向递送至多亚基结构的用途 |
| WO2016036937A1 (fr) * | 2014-09-05 | 2016-03-10 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| EA201791139A1 (ru) * | 2014-11-26 | 2018-04-30 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены |
| WO2016116626A1 (fr) * | 2015-01-23 | 2016-07-28 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh active
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/fr unknown
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 CA CA3030943A patent/CA3030943A1/fr active Pending
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Application Discontinuation
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja active Active
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/fr not_active Withdrawn
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI790206B (zh) | 2023-01-21 |
| PE20190514A1 (es) | 2019-04-10 |
| TW201811830A (zh) | 2018-04-01 |
| JP2022105138A (ja) | 2022-07-12 |
| CL2019000119A1 (es) | 2019-06-14 |
| SG11201900400QA (en) | 2019-02-27 |
| CO2019001367A2 (es) | 2019-02-19 |
| DOP2019000011A (es) | 2019-05-15 |
| US20190241657A1 (en) | 2019-08-08 |
| IL264248A (en) | 2019-02-28 |
| MX2019000844A (es) | 2019-07-04 |
| EA201990321A1 (ru) | 2019-06-28 |
| CN109715665A (zh) | 2019-05-03 |
| EP3484924A1 (fr) | 2019-05-22 |
| TN2019000015A1 (en) | 2020-07-15 |
| PH12019500122A1 (en) | 2019-04-15 |
| CA3030943A1 (fr) | 2018-01-25 |
| KR20190028771A (ko) | 2019-03-19 |
| ECSP19011185A (es) | 2019-02-28 |
| BR112019000770A2 (pt) | 2019-07-02 |
| WO2018015340A1 (fr) | 2018-01-25 |
| CR20190072A (es) | 2019-06-25 |
| AR109264A1 (es) | 2018-11-14 |
| JP2019531701A (ja) | 2019-11-07 |
| AU2017299125A1 (en) | 2019-03-07 |
| JP7071329B2 (ja) | 2022-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45680A (fr) | Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 | |
| MA54514A (fr) | Anticorps se liant à cd3 | |
| MA51734A (fr) | Anticorps se liant à gprc5d | |
| MA49038A (fr) | Anticorps bispécifiques se liant particulièrement à pd1 et lag3 | |
| MA43305A (fr) | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 | |
| CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| MA46893A (fr) | Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation | |
| MA41279A (fr) | Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux | |
| ECSP18000844A (es) | Anticuerpos de unión a tau | |
| MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
| KR102355950B9 (ko) | Tigit에 대한 항체 | |
| MA46917A (fr) | Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation | |
| MA43874A (fr) | Constructions de liaison à l'antigène immunomodulateur multispécifique | |
| MA42626A (fr) | Nouveaux anticorps anti-pd-1 | |
| MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
| CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA44072A (fr) | Anticorps se liant spécifiquement à hla-dr et leurs utilisations | |
| MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
| MA43019A (fr) | Anticorps anti-humain cd19 à affinité élevée | |
| MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
| ECSP18000887A (es) | Anticuerpos de unión a tau | |
| DK3164159T3 (da) | Bispecifikke cd33- og cd3-bindende proteiner | |
| DK3137504T3 (da) | Antistofbinding til fcrn til behandling af autoimmunsygdomme |